Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.

Abstract: The present invention relates to a pharmaceutical composition comprising at least one active compound having cytostatic activity, at least one biological electron acceptor and customary pharmaceutical additives, and to its use for the treatment of tumor diseases, in particular for the treatment of cancer.

Abstract: This invention relates to a pharmaceutical composition comprising as active principle, docetaxel or a taxoid derived from docetaxel, one or more unsaturated phospholipids and a small amount of one or more negative phospholipids, allow the active principle to be formulated in high concentration and are suitable for administration by injection.

Abstract: Pharmaceutical preparation containing phospholipids for the therapeutic treatment of rheumatic diseases which contain in addition to the antiphlogistically acting oxicam derivatives of the general formula ##STR1## special 1,2-diacyl-glycero-3-phosphocholines wherein 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals, and the preparation thereof.

Abstract: Pharmaceutical formulations for the treatment of gastrointestinal disorders, which contain as the active component an effective gastrointestinal disorder alleviating amount of a 1,2-diacylglycero-3-phosphocholine in which 75-86% by weight of the acyl radicals are unsaturated fatty acid radicals having a chain length of 16, 18 or 20 carbon atoms. The mixtures of fatty acid radicals in the acyl groups in the 1- and 2-positions preferably have different compositions. The formulations can also contain other active compounds, in particular those which display injurious gastrointestinal side effects.

Abstract: Phospholipid concentrates from natural or synthetic phospholipids and physiologically acceptable organic solvents and further additives of the following composition:20-60 wght. % phospholipids0-23 wght. % glycerin5-62.5 wght. % organic solvent0-30 wght. % co-emulsifier0-35 wght. % dissolving intermediary0-15 wght. % water0-15 wght. % vegetable oil or neutral oilThe phospholipids are a mixture of phosphatidyl choline, phosphatidyl ethanol amine, N-acetyl phosphatidyl ethanol amine, and other phosphatides, the concentrates perferably containing a mixture of 10-50 wght. % phosphatidyl choline, 10-30 wght. % phosphatidyl diethanol amine, 10-30 wght. % N-acylphosphatidyl ethanol amine, and 3-10 wght. % other phosphatides, in relation to the total quantity of phospholipids. The phospholipid concentrates are particularly suitable as auxiliary agents in the production and application of spray mixtures containing plant protectants.

Abstract: Liquid, active substance formulations containing an active substance insoluble or poorly soluble in water, or a mixture, a phospholipid, a special co-emulsifier (glycerinester in which the 1 or 2 OH groups have been esterized with hydrocarbon atoms of 8-16, preferably 8-10, C atoms by means of fatty acids and the 3 or remaining OH group of the glycerin body has been etherized with polyethyleneglycol, specifically, with 6-30, preferably 6-15 ethyleneoxide units) and a liquid carrier, the molar ratio of phospholipid to co-emulsifier being from 1:1 to 1:4, and the formulations being such that when added to water they form a transparent liquid system in the form of a microemulsion, with a degree of fineness of 10-200 nm in the lipid phase.

Abstract: Process for the application of plant protectant spray mixtures in which the phospholipid concentrates are applied to open ground, phospholipids being discharged along with commercially available, diluted effective ingredient concentrates and the spray mixtures being formed before discharge from the active ingredient concentrate, water, and the phospholipid concentrate. This process employs packing units which contain the active ingredient concentrate and the appropriate quantity of phospholipid concentrate in separate compartments.

Abstract: The invention provides N-propionylsarcosineanilides of the formula: ##STR1## wherein n is an integer of 1 to about 3 and the substituent A which can be the same or different when n is greater than 1 is selected from the group consisting of trifluoromethyl; halogen; nitro; acetyl; a straight-chain or branched alkyl group having 1 to 4 carbon atoms; a straight-chain or branched alkoxy group having 1 to 4 carbon atoms; a straight-chain or branched alkylmercapto group having 1 to 7 carbon atoms; a substituted alkylmercapto group of the formula: ##STR2## wherein n is an integer of 1 or 2, R.sub.1 can represent hydrogen and methyl, and R.sub.2 can represent hydroxyl, and an amino group of the formula:--NR.sub.6 R.sub.7 Vwherein R.sub.6 can represent hydrogen, and methyl, and R.sub.7 can represent methyl, substituted benzyl, and R.sub.6 and R.sub.7, together with the nitrogen, can constitute a substituted pyrrolidine ring; a sulphonyl group of the formula:--SO.sub.2 R.sub.3 IIIwherein R.sub.